EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitScoping ReviewOpen Access · CC BY 4.0

Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review

Loizos Hadjigeorgiou iD, Melina Yerolatsite iD, Nanteznta Torounidou, George Zarkavelis iD, Dimitrios Schizas iD, Vasileios Tatsis, Stefano Rausei iD, Konstantinos Vlachos, Georgios D Lianos

Journal of Clinical Medicine · 11.08.2026 · 15 (16) · 6222

DOI: 10.3390/jcm15166222 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 11.08.2026. Verfasst von Loizos Hadjigeorgiou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Circulating tumor DNA (ctDNA) is a promising non-invasive biomarker for detecting minimal residual disease (MRD) and predicting recurrence after curative treatment, yet evidence in esophageal squamous cell carcinoma (ESCC), esophageal adenocarcinoma (EAC), and gastric cancer has largely been examined within individual tumor types. In this scoping review, we mapped this evidence across all three malignancies and clarified key methodological and clinical considerations. Following the PRISMA-ScR guidelines, we searched PubMed, Scopus, and the Cochrane Library (3 April 2026) for studies linking ctDNA to disease-free, recurrence-free, or overall survival after curative-intent treatment. Twenty-seven studies (1746 patients; 10 ESCC, 4 EAC, 8 gastric, and 5 mixed) were included. Across every tumor type, postoperative ctDNA MRD was the most informative timepoint, with independent multivariable hazard ratios for disease-free, recurrence-free, or event-free survival of 2.8 to 21.8, whereas preoperative ctDNA was seldom prognostic. Serial monitoring further improved performance and flagged recurrence 78 to 278 days before imaging. Tumor-informed assays showed higher sensitivity than tumor-agnostic ones (80% vs. 35%), though direct comparisons were limited; correction for clonal hematopoiesis was essential for tumor-agnostic assays, and blood-based assays performed poorly in diffuse-type and peritoneal disease. Postoperative ctDNA MRD is a consistent, independent prognostic biomarker across upper gastrointestinal cancers that adds prognostic information beyond conventional staging and pathological response, supporting prospective interventional trials of ctDNA-guided management.

Schlagwörter

Stichwörter der Autor:innen

circulating tumor DNActDNAesophageal cancergastric cancerliquid biopsyminimal residual diseaseprognosisrecurrence

Autor:innen und Institutionen

  • Department of General Surgery, University Hospital of Ioannina, 45500 Ioannina, Greece.
  • Department of Medical Oncology, University Hospital of Ioannina, 45500 Ioannina, Greece.
  • First Department of Surgery, Laikon General Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
  • General Surgery Unit, Department of Surgery, Cittiglio-Angera Hospital, ASST Sette Laghi, 21100 Varese, Italy.

ORCID-Profile: Loizos Hadjigeorgiou, Melina Yerolatsite, George Zarkavelis, Dimitrios Schizas, Stefano Rausei

Zitieren

APA

Hadjigeorgiou, L., Yerolatsite, M., Torounidou, N., Zarkavelis, G., Schizas, D., Tatsis, V., Rausei, S., Vlachos, K., & Lianos, G. D. (2026). Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review. Journal of Clinical Medicine, 15(16), 6222. https://doi.org/10.3390/jcm15166222

Vancouver

Hadjigeorgiou L, Yerolatsite M, Torounidou N, Zarkavelis G, Schizas D, Tatsis V, et al. Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review. Journal of Clinical Medicine. 2026;15(16):6222. doi:10.3390/jcm15166222

BibTeX
@article{Hadjigeorgiou2026,
  author = {Hadjigeorgiou, Loizos and Yerolatsite, Melina and Torounidou, Nanteznta and Zarkavelis, George and Schizas, Dimitrios and Tatsis, Vasileios and Rausei, Stefano and Vlachos, Konstantinos and Lianos, Georgios D},
  title = {Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {16},
  pages = {6222},
  doi = {10.3390/jcm15166222}
}
Kostenlos starten →